| Title |
Novel Therapies in Acute Lymphoblastic Leukemia
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, August 2018
|
| DOI | 10.1007/s11899-018-0457-7 |
| Pubmed ID | |
| Authors |
Kathleen W. Phelan, Anjali S. Advani |
| Abstract |
Treatment options for patients with acute lymphoblastic leukemia (ALL) beyond standard chemotherapy have grown significantly in recent years. In this review, we highlight new targeted therapies in ALL, with an emphasis on immunotherapy. Major advances include antibody-based therapies, such as naked monoclonal antibodies, antibody-drug conjugates and bispecific T cell engaging (BiTE) antibodies, as well as adoptive cellular therapies such as chimeric antigen receptor (CAR) T cells. Apart from the above immunotherapeutic approaches, other targeted therapies are being employed in Philadelphia chromosome-positive (Ph+) ALL, Philadelphia-like (Ph-like) ALL, and T cell ALL. These new treatment strategies are changing the treatment landscape of ALL and challenging the current standard of care. Clinical trials will hopefully help determine how to best incorporate these novel therapies into existing treatment algorithms. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 87 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 18% |
| Student > Master | 11 | 13% |
| Other | 7 | 8% |
| Researcher | 7 | 8% |
| Student > Ph. D. Student | 7 | 8% |
| Other | 14 | 16% |
| Unknown | 25 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 28% |
| Biochemistry, Genetics and Molecular Biology | 12 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Nursing and Health Professions | 4 | 5% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 6 | 7% |
| Unknown | 31 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2018.
All research outputs
#18,645,475
of 23,099,576 outputs
Outputs from Current Hematologic Malignancy Reports
#329
of 431 outputs
Outputs of similar age
#254,165
of 330,419 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#10
of 12 outputs
Altmetric has tracked 23,099,576 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 431 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,419 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.